Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trichostatin A in onychomycosis
NCT07065773Phase 2Active, not recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trichostatin a in onychomycosis, sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Safety and Tolerability at 24 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
trichostatin a
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT07065773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065773.